drugset / Trial / NCT00741195
Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This trial will evaluate the efficacy and safety of docetaxel plus bevacizumab in patients with pretreated, advanced non small cell lung cancer (NSCLC).
Timeline
- Start
- 2008-04
- Primary completion
- 2016-10
- Completion
- 2016-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |